15 completed, 4 unknown, 3 recruiting, 3 terminated. 11 Phase 2, 5 Not applicable, 5 Phase 3, 3 Phase 1, 1 Early Phase 1.
Follow Pulmonary Sarcoidosis: new trials by email Literature Review of Pulmonary Sarcoidosis trials Research Report on Pulmonary Sarcoidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016) Tulisokibart, Placebo, Background prednisone therapy - Pulmonary Sarcoidosis | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 158 | 2026-11-06 | 2026-10-09 |
| An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations XTMAB-16, Placebo - Pulmonary Sarcoidosis | Phase 2 | Not yet recruiting | Xentria, Inc. | 182 | 2026-10-30 | 2026-10-21 |
| Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis OATD-01, Placebo - Pulmonary Sarcoidosis | Phase 2 | Recruiting | Molecure S.A. | 96 | 2024-03-21 | 2026-10-08 |
| An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis XTMAB-16 - Pulmonary Sarcoidosis | Phase 2 | Completed | Xentria, Inc. | 31 | 2024-03-01 | 2026-10-16 |
| Comparative Diagnostic Yield of Endobronchial Cryo Biopsy vs Forceps Biopsy in Patients With Suspected Sarcoidosis Cryobiopsy with liquid nitrogen, Endobronchial Forceps Biopsy - Sarcoidosis Lung, Pulmonary Sarcoidosis | Not applicable | Recruiting | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 150 | 2024-01-01 | 2025-03-03 |
| Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations XTMAB-16 or Placebo - Pulmonary Sarcoidosis | Phase 1 / Phase 2 | Active not recruiting | Xentria, Inc. | 32 | 2023-11-10 | 2026-10-02 |
| Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis Pulmonary Sarcoidosis, Chronic Beryllium Disease | Unknown | Assistance Publique - Hôpitaux de Paris | 200 | 2023-06-14 | 2023-11-02 | |
| Comparison of Different Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis Exercise- One-Legged, Exercise-Two-Legged - Pulmonary Sarcoidosis | Not applicable | Completed | Istanbul University - Cerrahpasa | 26 | 2023-03-01 | 2024-10-15 |
| Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg, Placebo - Pulmonary Sarcoidosis | Phase 3 | Completed | aTyr Pharma, Inc. | 268 | 2022-09-15 | 2026-06-04 |
| Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis Hydroxychloroquine + low-dose prednisone, Prednisone - Pulmonary Sarcoidosis | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 200 | 2022-03-01 | 2022-02-21 |
| Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis CMK389, Placebo - Pulmonary Sarcoidosis | Phase 2 | Completed | Novartis Pharmaceuticals | 62 | 2020-09-23 | 2025-04-13 |
| The Effect of Inspiratory Muscle Training and Breathing Exercises Combined With Upper Extremity and Trunk in Patients With Sarcoidosis Threshold IMT, breathing exercises combined with upper extremity and trunk - Pulmonary Sarcoidosis | Not applicable | Completed | Istanbul University - Cerrahpasa | 24 | 2020-01-15 | 2022-05-31 |
| Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo - Pulmonary Sarcoidosis | Phase 1 / Phase 2 | Completed | aTyr Pharma, Inc. | 37 | 2019-01-29 | 2023-07-18 |
| Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis [68Ga]Ga-DOTA-Siglec-9 - Healthy Subjects, Rheumatoid Arthritis | Not applicable | Enrolling by invitation | Turku University Hospital | 26 | 2018-11-23 | 2024-11-25 |
| Breath Analysis in Patients With Suspected Sarcoidosis: The VOCs-IS Study Breath Analysis, Pulmonary Function Tests, Blood sampling and storage for genetic analysis - Pulmonary Sarcoidosis | Completed | Manchester University NHS Foundation Trust | 54 | 2018-10-01 | 2021-11-02 | |
| CASPA: CArdiac Sarcoidosis in PApworth Interstitial Lung Disease, Pulmonary Sarcoidosis | Completed | Papworth Hospital NHS Foundation Trust | 104 | 2017-06-29 | 2023-06-18 | |
| Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis ACZ885, Placebo - Pulmonary Sarcoidosis | Phase 2 | Completed | Novartis Pharmaceuticals | 40 | 2016-12-19 | 2021-10-04 |
| Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis Methionine, DOTANOC - Pulmonary Sarcoidosis | Phase 2 / Phase 3 | Terminated | Turku University Hospital | 5 | 2016-05-01 | 2026-10-07 |
| Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS) Acthar gel - Sarcoidosis, Pulmonary Sarcoidosis | Phase 4 | Unknown | University of Cincinnati | 20 | 2014-06-01 | 2015-12-08 |
| A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis PD 0360324, Normal Saline for injection - Pulmonary Sarcoidosis | Phase 2 | Terminated | Pfizer | 1 | 2013-03-15 | 2020-01-06 |
Showing 20 of 29. Sign in to see all of them.
Sarcoidosis, Pulmonary (29) · Sarcoidosis (13) · Granuloma (3) · Inflammation (3) · Lung Diseases, Interstitial (3) · Lung Diseases (2) · Lymphoproliferative Disorders (2) · Arthritis, Rheumatoid (1) · Asthma (1) · Autoimmune Diseases (1) · Cystic Fibrosis (1) · Fatigue (1) · Fibrosis (1) · Influenza, Human (1) · Motor Activity (1)
Hemic and Lymphatic Diseases (29) · Hypersensitivity (29) · Hypersensitivity, Delayed (29) · Immune System Diseases (29) · Lymphatic Diseases (29) · Respiratory Tract Diseases (29) · Lung Diseases (27) · Lymphoproliferative Disorders (27) · Lung Diseases, Interstitial (26) · Sarcoidosis (16) · Pathological Conditions, Signs and Symptoms (5) · Pathologic Processes (4) · Immunoproliferative Disorders (2) · Infections (2) · Actinomycetales Infections (1)
Hydroxychloroquine (2) · Prednisone (2) · 68Ga-DOTANOC (1) · Acetylcysteine (1) · Adrenocorticotropic Hormone (1) · Azithromycin (1) · Blood Specimen Collection (1) · Bronchoalveolar Lavage (1) · Ethambutol (1) · Genetic Testing (1) · Influenza Vaccines (1) · Injections (1) · Levofloxacin (1) · Methionine (1) · Mycophenolic Acid (1)
Xentria, Inc. (3) · Assistance Publique - Hôpitaux de Paris (2) · Istanbul University - Cerrahpasa (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Novartis Pharmaceuticals (2) · Turku University Hospital (2) · aTyr Pharma, Inc. (2) · Elliott Crouser MD (1) · Manchester University NHS Foundation Trust (1) · Medical University of South Carolina (1) · Meir Medical Center (1) · Merck Sharp & Dohme LLC (1) · Molecure S.A. (1) · National Jewish Health (1) · Papworth Hospital NHS Foundation Trust (1)
United States (15) · United Kingdom (7) · Germany (4) · Czechia (3) · Denmark (3) · France (3) · Netherlands (3) · Poland (3) · Finland (2) · Italy (2) · Spain (2) · Turkey (Türkiye) (2) · Brazil (1) · Greece (1) · India (1)
Ajmal Khan, MBBS, MD, DM (1) · Alberto Pesci (1) · Amirsoheil Talebian, MD (1) · Anne Roivainen, Professor (1) · Dariusz Stencel, MD (1) · Don C Rockey, MD (1) · Elliott D. Crouser, M.D. (1) · Gennyne Walker (1) · Joel Moss, M.D. (1) · Juhani Knuuti, MD, PhD (1) · Lisa Carey (1) · Marc A Judson, MD (1)
PMID 24284293, PMID 28353116, PMID 30291925, PMID 36356657, PMID 37854715, PMID 37902990, PMID 41015397, PMID 41420234
2023 (1), 2025 (1)